PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts

Simone Thomsen (center), Chair of PhRMA Japan-based Executive Committee, PhRMA Japan Representative Hans Klemm (right) Meet Press in Tokyo on April 3 The Pharmaceutical Research and Manufacturers of America (PhRMA) welcomes Japan’s 2024 drug pricing reform, but more work needs...read more